Efficacy and Safety of Zihua Wenfei Granules in Treatment of Postinfectious Cough (Wind-cold Invading Lungs Syndrome)

Efficacy and Safety of Zihua Wenfei Granules in Treatment of Postinfectious Cough (Wind-cold Invading Lungs Syndrome): a Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial

Cough is a common symptom of respiratory medicine clinic patients, which has complex etiology and wide-ranging. Cough is usually divided into three categories by time: acute cough, subacute cough and chronic cough. Subacute cough has a 3~8 weeks course of disease. Its main etiology is postinfectious cough, which is mostly secondary to viral infection.The drug in this study is for post-infection cough in subacute cough. After long-term clinical practice, six traditional Chinese medicines, including Aster, Lonicera japonica, Shegan, dried ginger, mango seed and Schizonepeta tenuifolia, were selected to form Zihua Wenfei Zhisou Decoction. This product has the effect of relieving wind, relieving cough, warming the lung and resolving phlegm. It can be used for the cough syndrome caused by Wind-cold invading lungs syndrome. The aim is to evaluate the efficacy and safety of Zihua Wenfei Zhisou Granule in the treatment of postinfection cough (wind-cold lung syndrome) with placebo as a control.

Study Overview

• Status: Recruiting
• Conditions: Cough
• Intervention / Treatment: Drug: Zihua Wenfei Zhisou Granule; Drug: Placebo

Detailed Description

Patients in treatment arm were given Zihua Wenfei Zhisou Granule (15 g/bag, one bag at a time, three times/day). Patients in placebo treatment arm were given Zihua Wenfei Zhisou Granule-matched placebo (15 g/bag, one bag at a time, three times/day). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients. After that, there will be a follow-up 14 days after drug withdrawal.

• Study Type: Interventional
• Enrollment (Anticipated): 480
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Bing Mao; Phone Number: 18980601724; Email: maobing@medmail.com.cn
• Study Contact Backup: Name: Hongli Jiang; Phone Number: 18980606651; Email: doc_jhl@163.com

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China
      • Recruiting
      • West China Hospital of Sichuan University
      • Contact: Bing Mao; Phone Number: 18980601724; Email: maobing@medmail.com.cn
      • Contact: Hongli Jiang; Phone Number: 18980606651; Email: doc_jhl@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• When signing the informed consent form, the age is between 18 and 65 years old (including 18 and 65 years old)；
• Diagnosis of postinfectious cough;
• Wind-cold invading lungs syndrome in TCM Zheng;
• Baseline cough visual analogue scale of 60 mm or more;
• Cough duration of 3- 6 weeks;
• Voluntarily provide written and informed consent.

Exclusion Criteria:

• Cough caused by cough variant asthma, upper airway cough syndrome, eosinophilic bronchitis, gastroesophageal reflux cough or any other concomitant conditions;
• Patients with severe pulmonary diseases such as lung cancer, lung tuberculosis, or lung fibrosis;
• After inhaling bronchodilator, patients with FEV1/FVC<70% were excluded;
• Subjects who have taken angiotensin-converting-enzyme inhibitor (ACEI) in the past month;
• Current smokers or recent ex-smokers quitting smoking less than 3 months ago;
• FeNO ≥ 32 ppb or Bronchial provocation test positive (for FeNO and Bronchial provocation test, if the center cannot detect it, it can be detected in other qualified tertiary hospitals);
• Combined with serious cardio-cerebrovascular diseases, malignant tumors, diseases of blood and hematopoietic system, gastrointestinal diseases or other serious or progressive diseases of the system; Or those who are unable to cooperate or unwilling to cooperate due to severe mental illness, severe cognitive impairment, etc;
• Liver and kidney dysfunction: ALT or AST >2 times the upper limit of normal reference value; And/or serum creatinine >1.5 times the upper limit of normal reference value, or eGFR< 60 mL/min/1.73m2;
• White blood cell count < 3.0×109/L or > 10.0×109/L, and/or neutrophil granulocyte > 80%;
• Patients with temperature of 37.3℃ or above;
• Patients taking similar medications in the last one week;
• Have a long history of alcohol or drug abuse;
• Pregnancy or potential pregnancy or lactation;
• Allergic constitution or known to be allergic to any component in tested drug;
• Patients having participated or participating in another trial in last 3 month;
• Patients unsuitable for clinical trials judged by researchers.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Zihua Wenfei Zhisou Granule; Patients in experimental treatment arm were given Zihua Wenfei Zhisou Granule (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients.	Drug: Zihua Wenfei Zhisou Granule; 14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
Placebo Comparator: Zihua Wenfei Zhisou Granule-matched placebo; Patients in placebo treatment arm were given Zihua Wenfei Zhisou Granule-matched placebo (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients. Placebo does not contain active pharmaceutical ingredients, and its main ingredients are lactose, beta-cyclodextrin, stevioside, and caramel.	Drug: Placebo; 14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cough relief rate	Cough relief refers to a 50% or more reduction in cough VAS score	day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete remission rate of cough	Complete remission of cough refers to cough VAS score<17 mm	day 14
Time to cough relief	Time to cough relief	day 14
Complete remission time of cough	Complete remission time of cough	day 14
Change from baseline in Cough Evaluation Test (CET) value	Change from baseline in Cough Evaluation Test (CET) value	day 0、day 7、day 14
Change from baseline in visual analogue scale (VAS) value	The visual analogue scale (VAS) is a 100 mm scale, with a minimum value of 0 mm and a maximum value of 100 mm. 0 mm means that the cough is not troubled at all, and 100 mm means that the cough is the most troubled.	day 0、day 7、day 14
Change from baseline in TCM syndrome score	Change from baseline in TCM syndrome score	day 0、day 7、day 14
Change from baseline in Leicester Cough Questionnaire (LCQ) score	The LCQ comprises 19 items and takes 5 to 10 minutes to complete. The LCQ is a validated QoL measurement tool for non-specific cough and assesses the impact of cough on various aspects of life, including emotions, sleeping behaviour, work and relationships. It contains 19 items which are divided over 3 domains: physical (8 items), psychological (7 items) and social (4 items), with a 7-point Likert response scale.	day 0、day 14、day 28

Collaborators and Investigators

• Sponsor: DoCare Pharmaceutial Technology Co.,Ltd

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2022
• Primary Completion (Anticipated): November 1, 2023
• Study Completion (Anticipated): August 1, 2024

Study Registration Dates

• First Submitted: February 24, 2023
• First Submitted That Met QC Criteria: March 7, 2023
• First Posted (Actual): March 13, 2023

Study Record Updates

• Last Update Posted (Actual): March 13, 2023
• Last Update Submitted That Met QC Criteria: March 7, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Cough
• Other Study ID Numbers: KCDC-ZHWFZSKLⅢ-2022

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No